Yazar "Alemdar, R." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Assessment of cardiac functions in patients with adenotonsillar hypertrophy
    (Duzce University Medical School, 2011) Ordu, Serkan; Özhan, H.; Uzun, H.; Alemdar, R.; Erden, I.; Yazıcı, M.; Gültekin E.
    Background: The aim of this study is to compare cardiac function in children with and without adenotonsillar hypertrophy (ATH). Materials and methods: Ninety-one children (26 female 65 male) who were diagnosed as ATH in the pediatric outpatient clinic and twenty-three completely healthy, age-sex matched children (10 female 13 male) were included in the study. All patients underwent a complete twodimensional transthoracic echocardiographic and Doppler study. Results: Mean mitral E, A and deceleration time were significantly longer in ATH group. Also chamber areas and volumes were bigger. Pulmonary and mitral regurgitation were statistically more frequent in ATH group. Adenotonsillar grade was positively related with mean pulmonary arterial pressure (r: 0.44 p: <0.001). Mitral valve thickness was strongly correlated with tonsillar hypertrophy grade (r: 0.73; p.<0.001). Conclusions: ATH may lead to mild diastolic dysfunction and chamber dilatation. Mitral valve thickness was strongly correlated with adenotonsillar grade. © 2011 Düzce Medical Journal.
  • Küçük Resim
    Öğe
    THE IMPACT OF PIOGLITAZONE THERAPY ON GLYCEMIC CONTROL, BLOOD PRESSURE AND INFLAMMATORY MARKERS IN PATIENTS WITH DIABETES MELLITUS
    (Editura Acad Romane, 2010) Ordu, Serkan; Güngör, A.; Yüksel, H.; Alemdar, R.; Özhan, H.; Yazıcı, M.; Albayrak, S.
    Aim. The aim of our study was to investigate the effect of pioglitazone on glycemic and blood pressure control, on inflammation markers in diabetic patients. Patients and methods. Forty-nine diabetic patients who had been followed up as outpatients for 2.7 years and HbA1c was >7% were included in the study. The patients had never received thiazolidinedione therapy before. Clinical, metabolic variables, high-sensitive C-reactive protein (hsCRP), homocysteine (HCY) and asymmetric dimethylarginine (ADMA) levels were measured. 30 mg pioglitazone were administered. The patients were followed up for six months and all the measurements were re-evaluated for comparison. Results. Body mass index (BMI) significantly increased after treatment. Fasting glucose, HbA1c and HsCRP were decreased. Insulin resistance was improved and HOMA-IR index was decreased after pioglitazone treatment [8 (+/- 6.5) vs 4(+/- 3.1); p<0.00011. Pioglitazone improved lipid metabolism. Mean total cholesterol and LDL cholesterol levels were decreased and HDL cholesterol was increased after treatment. The decrease in triglyceride and homocysteine levels did not reach significance. Mean ADMA level did not change after therapy [0.62 (+/- 0.39) vs 0.61 (+/- 0.44); p=0.85]. Conclusion. Pioglitazone treatment in type 2 DM produced significant improvements in measures of glycemic control, plasma lipids, blood pressure and homocysteine levels. Pioglitazone had no influence on ADMA levels.
  • Küçük Resim Yok
    Öğe
    Lifestyle modification decreases the mean platelet volume in prehypertensive patients [conferenceObject]
    (Oxford Univ Press, 2009) Özhan, Hakan; Yazıcı, M.; Kaya, A.; Albayrak, E.S.; Ordu, S.; Alemdar, R.; Aydın, M.
    …